- Home
- AIG vs ALNY Comparison
AIG vs ALNY Comparison
Compare AIG & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AIG | ALNY |
|---|---|---|
| Founded | 1919 | 2002 |
| Country | United States | United States |
| Employees | N/A | 115 |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7B | 38.4B |
| IPO Year | 2006 | 2004 |
Fundamental Metrics
Financial Performance| Metric | AIG | ALNY |
|---|---|---|
| Price | $74.04 | $276.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 28 |
| Target Price | $86.46 | ★ $471.00 |
| AVG Volume (30 Days) | ★ 3.2M | 955.3K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | ★ 350.23 | 206.88 |
| EPS | 1.41 | ★ 2.33 |
| Revenue | ★ $26,775,000,000.00 | $1,037,418,000.00 |
| Revenue This Year | $11.55 | $52.67 |
| Revenue Next Year | $5.26 | $31.48 |
| P/E Ratio | ★ $52.98 | $120.11 |
| Revenue Growth | N/A | ★ 22.88 |
| 52 Week Low | $71.25 | $276.94 |
| 52 Week High | $87.35 | $495.55 |
Technical Indicators
Market Signals| Indicator | AIG | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 43.82 | 37.45 |
| Support Level | $72.50 | N/A |
| Resistance Level | $79.19 | $314.04 |
| Average True Range (ATR) | 1.42 | 10.34 |
| MACD | 0.05 | -1.44 |
| Stochastic Oscillator | 43.41 | 7.22 |
Price Performance
Historical ComparisonAbout AIG American International Group Inc. New
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. The company recently spun off its life insurance operations (Corebridge), but still retains a minority stake.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.